Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164657 | 0.86 | DRD3 (0.47) | HRH4KDM4E | |
| SCHEMBL4666072 | 0.85 | SRC (0.45) | SRCPRKCQPRKCDDNMT1EHMT2 | |
| SCHEMBL7167588 | 0.80 | KMT2A (0.43) | HRH4KDM4E | |
| SCHEMBL4666061 | 0.80 | FGFR2 (0.46) | SRCDNMT1EHMT2FYN | |
| SCHEMBL4666067 | 0.78 | EGFR (0.39) | SRCDNMT1EHMT2 | |
| SCHEMBL13980555 | 0.74 | EGFR (0.46) | SRCHRH4EHMT2KDM4EFYN | |
| SCHEMBL4664125 | 0.74 | SRC (0.46) | SRCDNMT1EHMT2FYN | |
| SCHEMBL4666490 | 0.74 | SRC (0.46) | SRCDNMT1EHMT2FYN | |
| SCHEMBL7163046 | 0.72 | DRD3 (0.52) | HRH4 | |
| SCHEMBL4664589 | 0.72 | PRKCQ (0.46) | SRCPRKCQPRKCDFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | SRC 3356/4885HRH4 72/4885PRKCQ 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.